Novartis | NVS - Przychody Ze Sprzedaży





Obroty Zmiana Data
AbbVie USD 15B 1.62B 2026-03
Amgen USD 8.62B 1.28B 2026-03
AstraZeneca USD 15.29B 213M 2026-03
Bausch Health Companies USD 2.5B 300M 2026-03
Biogen USD 2.25B 30M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Canopy Growth CAD 71.25M 3.29M 2026-03
Corcept Therapeutics USD 164.9M 37.22M 2026-03
Drreddys Laboratories INR 789.05M 86.48B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Gilead Sciences USD 7B 930M 2026-03
GlaxoSmithKline GBP 7.63B 991M 2026-03
Glaxosmithkline GBP 10.09B 1.37B 2026-03
J&J USD 25.31B 1.21B 2026-06
Merck USD 16.29B 110M 2026-03
Novartis USD 14.41B 1.3B 2026-06
Novartis USD 13.11B 750M 2026-03
Pacira USD 177M 19.87M 2026-03
Perrigo USD 969M 141M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Phibro Animal Health USD 373.91M 10.02M 2025-12
Prestige Brands USD 281.62M 1.82M 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Sanofi EUR 11.24B 60M 2026-03
Sanofi EUR 12.14B 65M 2026-03
Supernus Pharmaceuticals USD 207.71M 3.89M 2026-03
Zoetis USD 2.3B 100M 2026-03